Laboratory Products xxvii Cutting-edge solutions for precision and sterility in aseptic fill-finish
Increased demand for injectable drugs and stricter regulations drive surge in aseptic fill-finish technology, with Biopharma Group emerging as a trusted partner for UK and Irish pharma companies.
Why is aseptic fill-finish critical? This process safeguards the efficacy, integrity, and ultimately, the safety of sterile medications. With the UK and Ireland’s aseptic fill-finish market projected to reach £3.8 billion by 2025, Biopharma Group highlights the importance of:
• Precision: Choosing the right equipment for accurate dosing and sterility is paramount. • Compliance: Modern systems prioritise features like validated cleaning, data integrity, and container closure integrity testing. • Patient Safety: Integrated cleanroom environments, advanced sterilisation technologies, and automated inspection systems minimise contamination risks.
Case Study: A leading pharmaceutical company reduced waste, increased efficiency, and improved product quality with Biopharma Group’s aseptic fill-finish solutions. The results were very impressive:
• 50% reduction in waste product • 20% increase in production efficiency • 30% reduction in downtime • Significant improvement in product quality observed • Clear return on investment
Biopharma Group’s Value Proposition: • Partnerships: Collaborating with ATS Scientific Life Sciences, Biopharma Group offers a comprehensive equipment range.
• Expertise: 35 years of experience in the UK and Irish markets. • Solutions:
- Aseptic fill-finish equipment: Isolators, RABS, filling lines, inspection systems - Freeze dryers and lyo services: Expertise in lyophilisation with advanced freeze dryers and validated processes - Technical support and training: Comprehensive support throughout the process
Elevate your injectable drug production with Biopharma Group’s commitment to precision and sterility in aseptic fill-finish. Contact Biopharma Group today to discuss your requirements.
More information online:
ilmt.co/PL/eNpb and
ilmt.co/PL/EVMV 62045pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94
